Ethics and eplerenone
Share this article
Click the icon of the social media platform on which you would like to share this article.
Email this article to a friend
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Other content recommended for you
- Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms
- The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future
- Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment
- Aldosterone antagonists improve ejection fraction and functional capacity independently of functional class: a meta-analysis of randomised controlled trials
- Long-term effect of cardiac resynchronisation in patients reporting mild symptoms of heart failure: a report from the CARE-HF study
- An evidence-based review of recent advances in therapy for heart failure with reduced ejection fraction (HFrEF)
- Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure
- Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia
- Is there benefit in implanting defibrillators in patients with severe heart failure?
- Added value of a physician-and-nurse-directed heart failure clinic: results from the Deventer–Alkmaar heart failure study